Biobot, a Singapore-based firm which makes a speciality of robotic prostate biopsy and therapy options, raised $24M in Sequence B funding.
The spherical was led by Mr. Tony Tan, with participation from ZIG Ventures, and the brand new strategic buyers.
The corporate intends to make use of the funds to broaden its presence worldwide and additional develop its digital surgical procedure infrastructure.
Biobot is devoted to redefining the usual of care in urology by way of technological innovation. Its flagship product, the iSR’obot Mona Lisa system, offers urologists with robotic precision and enhanced visualization for percutaneous transperineal procedures.
The expertise is already getting used globally greater than 50 Mona Lisa robots deployed, and over 20,000 procedures accomplished.
FinSMEs
08/03/2024
